Clarity Receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA

Clarity Receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA

By, Admin 24 August 2024

Overview

Clarity Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for its 64Cu-SAR-bisPSMA, a diagnostic agent designed for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive prostate cancer lesions in patients suspected of having metastasis and who are candidates for initial definitive therapy.

About 64Cu-SAR-bisPSMA

  • 64Cu-SAR-bisPSMA represents a significant advancement in prostate cancer diagnosis. 
  • This innovative product enables next-day imaging and has demonstrated higher tumor uptake and retention, along with the ability to detect much smaller lesions. 

Impact of Longer half Life

  • The longer half-life of copper-64 also results in an extended shelf-life compared to currently available diagnostic radiopharmaceuticals, facilitating centralized manufacturing and broader distribution while supporting more flexible patient scheduling—advantages not offered by gallium-68 and fluorine-18 based diagnostics.

Clinical Program Groups: -

The ongoing clinical program for 64Cu-SAR-bisPSMA includes trials in two key patient groups: 

those with prostate cancer scheduled for radical prostatectomy, and those experiencing biochemical recurrence (BCR) of the disease. 

Phase I PROPELLER Study Results

The completed Phase I PROPELLER study yielded favorable safety and efficacy results in patients prior to radical prostatectomy, leading to the initiation of a registrational Phase III trial, CLARIFY, which is currently recruiting participants.

About Phase I/II COBRA Trial

  • Concurrently, the Phase I/II COBRA trial demonstrated that 64Cu-SAR-bisPSMA is both safe and highly effective in detecting prostate cancer lesions in patients with BCR. Based on the promising outcomes of the COBRA study, Clarity is planning a second registrational Phase III imaging trial. 
  • The FDA’s fast track designation is supported by initial clinical evidence suggesting that 64Cu-SAR-bisPSMA may offer superior lesion detection compared to existing prostate cancer diagnostics.

This designation underscores the potential of 64Cu-SAR-bisPSMA to provide a novel diagnostic solution for prostate cancer patients, addressing the limitations of current-generation diagnostic radiopharmaceuticals.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!